IS6925A - Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns - Google Patents

Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns

Info

Publication number
IS6925A
IS6925A IS6925A IS6925A IS6925A IS 6925 A IS6925 A IS 6925A IS 6925 A IS6925 A IS 6925A IS 6925 A IS6925 A IS 6925A IS 6925 A IS6925 A IS 6925A
Authority
IS
Iceland
Prior art keywords
tegafur
carboplatin
paclitaxel
uracil
tumors
Prior art date
Application number
IS6925A
Other languages
English (en)
Inventor
A. Ajani Jafferhusen
E. Benner Steven
S. Dugan Terry
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS6925A publication Critical patent/IS6925A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS6925A 2001-03-06 2003-08-22 Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns IS6925A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (1)

Publication Number Publication Date
IS6925A true IS6925A (is) 2003-08-22

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6925A IS6925A (is) 2001-03-06 2003-08-22 Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns

Country Status (20)

Country Link
US (1) US6770653B2 (is)
EP (1) EP1368034A1 (is)
JP (1) JP2005506294A (is)
KR (1) KR20030081496A (is)
BR (1) BR0207443A (is)
CA (1) CA2439676A1 (is)
CZ (1) CZ20032266A3 (is)
EE (1) EE200300429A (is)
HR (1) HRP20030801A2 (is)
HU (1) HUP0303466A3 (is)
IL (1) IL157357A0 (is)
IS (1) IS6925A (is)
MX (1) MXPA03007989A (is)
NO (1) NO20033910L (is)
PL (1) PL363967A1 (is)
RU (1) RU2284184C2 (is)
SK (1) SK10602003A3 (is)
WO (1) WO2002076459A1 (is)
YU (1) YU69903A (is)
ZA (1) ZA200306541B (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391083B2 (ja) * 2000-11-06 2009-12-24 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
ES2312978T3 (es) 2003-03-14 2009-03-01 Taiho Pharmaceutical Co., Ltd. Potenciador del efecto antitumoral y agente antitumoral.
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
UA87877C2 (en) * 2004-10-26 2009-08-25 Фарма Мар С.А., Сосьедад Униперсональ Pegylated liposomal doxorubicin in combination with ecteinescidin 743
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Et−743治療のための予後分子マーカー
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス, エルエルシー 膵臓がんの処置方法
WO2016172393A1 (en) * 2015-04-22 2016-10-27 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
RU2752172C2 (ru) 2016-08-31 2021-07-23 Фуджифилм Корпорэйшн Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
AU2018404329B2 (en) 2018-01-29 2021-09-09 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Also Published As

Publication number Publication date
HUP0303466A3 (en) 2005-02-28
MXPA03007989A (es) 2003-12-04
KR20030081496A (ko) 2003-10-17
PL363967A1 (en) 2004-11-29
US20020173482A1 (en) 2002-11-21
NO20033910L (no) 2003-10-23
US6770653B2 (en) 2004-08-03
HUP0303466A2 (hu) 2004-01-28
ZA200306541B (en) 2004-11-22
SK10602003A3 (en) 2004-10-05
NO20033910D0 (no) 2003-09-04
CZ20032266A3 (cs) 2004-02-18
YU69903A (sh) 2006-08-17
CA2439676A1 (en) 2002-10-03
WO2002076459A1 (en) 2002-10-03
IL157357A0 (en) 2004-02-19
HRP20030801A2 (en) 2004-08-31
RU2003129527A (ru) 2005-03-10
RU2284184C2 (ru) 2006-09-27
BR0207443A (pt) 2004-04-06
EE200300429A (et) 2003-12-15
JP2005506294A (ja) 2005-03-03
EP1368034A1 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
WO2002062763A3 (en) Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2003080582A3 (de) Fredericamycin-derivate
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
ATE380807T1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
DE50310516D1 (de) Fredericamycin-derivate
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
AU2003245989A8 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
NO20034690L (no) Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid
HK1060518A (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole
NO20060045L (no) Indolederivater med apoptoseinduserende effekt